Cargando…

“Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients

EGFR TKIs are not curative, and targeted resistance inevitably results in therapeutic failure. Additionally, there are numerous uncommon EGFR mutations that are insensitive to EGFR TKIs, and there is a lack of clinical strategies to overcome these limitations. EGFR TKI and mAbs target EGFR at differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Guoqing, Yan, Beibei, Guo, Yanan, Yang, Hang, Li, Jindong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321780/ https://www.ncbi.nlm.nih.gov/pubmed/35903676 http://dx.doi.org/10.3389/fonc.2022.952939

Ejemplares similares

Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy
por: Zhang, Guoqing, et al.
Publicado: (2022)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management
por: Abdullah, Shaad E., et al.
Publicado: (2012)

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
por: Cai, Wen-Qi, et al.
Publicado: (2020)

Radiomic Feature-Based Nomogram: A Novel Technique to Predict EGFR-Activating Mutations for EGFR Tyrosin Kinase Inhibitor Therapy
por: Weng, Qiaoyou, et al.
Publicado: (2021)

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report
por: Wang, Pascal, et al.
Publicado: (2022)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis
por: Luo, Wenqing, et al.
Publicado: (2021)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

“Sandwich Therapy”—Immunotherapy Plus Concurrent Chemoradiotherapy for Advanced Esophagogastric Junction Carcinoma: Report of Two Cases and Literature Review
por: Wu, Lei, et al.
Publicado: (2022)

Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer
por: Cui, Nai-Peng, et al.
Publicado: (2021)

High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
por: Ma, Chunhua, et al.
Publicado: (2020)

Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2022)

Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
por: Chang, Cheng-Yu, et al.
Publicado: (2023)

Monoclonal Antibody-Based Sandwich ELISA for the Detection of Staphylococcal Enterotoxin A
por: Kuang, Hua, et al.
Publicado: (2013)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

Tyrosine kinases in nodal peripheral T-cell lymphomas
por: Piccaluga, Pier Paolo, et al.
Publicado: (2023)

Predicting Tyrosine Kinase Inhibitor Treatment Response in Stage IV Lung Adenocarcinoma Patients With EGFR Mutation Using Model-Based Deep Transfer Learning
por: Hou, Runping, et al.
Publicado: (2021)

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
por: Hsia, Te‐Chun, et al.
Publicado: (2018)

Adding Concurrent Chemotherapy Significantly Improves the Survival of Stage II-IVb Nasopharyngeal Carcinoma Patients Treated With Concurrent Anti-EGFR Agents
por: Yu, Zi-Kun, et al.
Publicado: (2021)

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
por: Wang, Feng, et al.
Publicado: (2019)

Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA
por: Zhang, Aixia, et al.
Publicado: (2012)

Detection of ruminant meat and bone meal in feeds by sandwich ELISA with monoclonal antibodies
por: YAMAMOTO, Takayuki, et al.
Publicado: (2015)

Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis
por: Xu, Jinhe, et al.
Publicado: (2022)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
por: Hu, Chi-Hao, et al.
Publicado: (2023)

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer
por: Chen, Lily, et al.
Publicado: (2022)

Monoclonal antibodies in cervical malignancy-related HPV
por: Aghbash, Parisa Shiri, et al.
Publicado: (2022)

The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
por: Wang, Huan, et al.
Publicado: (2014)

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
por: Guo, Yijia, et al.
Publicado: (2020)

Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization
por: Gan, Hui K, et al.
Publicado: (2009)

Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
por: Dong, Qian, et al.
Publicado: (2022)

First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations
por: Hu, Xiaolong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c8tvnqgpf75112h8gcisiehpa8